Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
The operational efficiency of the organization exhibits a period of relative stability interrupted by specific fluctuations in working capital utilization and a gradual expansion of the cash conversion cycle toward the end of the analyzed period.
- Inventory Management
- Inventory turnover remained largely consistent, fluctuating between a high of 4.15 in December 2024 and a low of 3.20 in June 2026. Correspondingly, the average inventory processing period typically ranged between 88 and 104 days. A notable deterioration in efficiency occurred in mid-2026, where the processing period peaked at 114 days, suggesting a slowdown in inventory movement during that quarter.
- Receivables Management
- Receivables turnover demonstrated steady performance, maintaining a range between 6.09 and 7.15. The average receivable collection period showed minimal volatility, consistently hovering between 51 and 60 days. This indicates a disciplined and predictable credit collection process throughout the entire duration of the analysis.
- Payables Management
- The payables turnover ratio fluctuated within a narrow band from 5.00 to 6.09. The average payables payment period remained stable, generally oscillating between 60 and 73 days. The consistency in these figures suggests a stable relationship with suppliers and a standardized approach to managing short-term obligations.
- Working Capital Efficiency
- Working capital turnover experienced significant volatility. After reaching a low of 2.18 in September 2023, the ratio climbed sharply to a peak of 8.85 by December 2024. This surge indicates a period of highly efficient asset utilization or a significant reduction in net working capital relative to revenue. However, the ratio subsequently corrected, returning to a range between 3.83 and 4.76 by late 2026.
- Operating and Cash Conversion Cycles
- The operating cycle generally remained between 142 and 163 days, although it spiked to 172 days in June 2026, driven primarily by the increase in inventory processing time. Consequently, the cash conversion cycle showed a general upward trend, rising from 75 days in April 2022 to 107 days by September 2026. This expansion suggests that more capital is being tied up in operations for longer durations over time.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Inventory Turnover
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cost of sales | 2,717) | 2,654) | 2,360) | 2,872) | 2,530) | 2,413) | 2,230) | 2,648) | 2,397) | 2,315) | 2,309) | 2,626) | 2,349) | 2,594) | 2,287) | 3,430) | 3,079) | 3,030) | 2,983) | ||||||
| Inventories | 3,134) | 3,260) | 2,608) | 2,489) | 2,674) | 2,689) | 2,532) | 2,330) | 2,678) | 2,671) | 2,645) | 2,594) | 3,024) | 3,183) | 3,383) | 3,110) | 3,236) | 3,257) | 3,072) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Inventory turnover1 | 3.38 | 3.20 | 3.90 | 4.04 | 3.67 | 3.60 | 3.79 | 4.15 | 3.60 | 3.59 | 3.73 | 3.80 | 3.53 | 3.58 | 3.50 | 4.03 | 3.80 | 3.71 | 3.87 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | 3.58 | 3.65 | 3.68 | 3.65 | 3.42 | 3.71 | 4.04 | 4.09 | 4.86 | 4.83 | 4.98 | 4.74 | 4.30 | 4.53 | 4.87 | 5.54 | 4.99 | 4.96 | ||||||
| Amgen Inc. | — | 1.87 | 1.91 | 1.93 | 1.92 | 1.88 | 1.88 | 1.84 | 1.75 | 1.42 | 1.14 | 0.89 | 1.41 | 1.38 | 1.31 | 1.30 | 1.34 | 1.40 | 1.48 | ||||||
| Bristol-Myers Squibb Co. | — | 5.36 | 5.20 | 5.18 | 5.31 | 5.18 | 5.28 | 5.46 | 3.57 | 3.72 | 3.70 | 4.02 | 4.33 | 4.39 | 3.93 | 4.33 | 4.77 | 4.59 | 4.55 | ||||||
| Eli Lilly & Co. | — | 0.79 | 0.85 | 0.80 | 0.83 | 0.84 | 0.96 | 1.11 | 1.05 | 1.16 | 1.17 | 1.23 | 1.40 | 1.37 | 1.36 | 1.54 | 1.86 | 1.79 | 1.93 | ||||||
| Gilead Sciences Inc. | — | 3.18 | 3.21 | 3.51 | 3.47 | 3.40 | 3.55 | 3.66 | 3.62 | 3.33 | 3.59 | 3.64 | 3.49 | 3.45 | 3.57 | 3.75 | 4.71 | 4.50 | 4.50 | ||||||
| Johnson & Johnson | 2.10 | 2.08 | 2.13 | 2.13 | 2.08 | 2.17 | 2.24 | 2.21 | 2.15 | 2.20 | 2.32 | 2.37 | 2.46 | 2.23 | 2.36 | 2.49 | 2.68 | 2.69 | 2.77 | ||||||
| Merck & Co. Inc. | — | 2.90 | 2.65 | 2.46 | 2.27 | 2.25 | 2.43 | 2.49 | 2.45 | 2.39 | 2.42 | 2.54 | 2.63 | 2.66 | 2.72 | 2.95 | 3.10 | 3.06 | 2.74 | ||||||
| Pfizer Inc. | — | 1.72 | 1.57 | 1.51 | 1.46 | 1.52 | 1.60 | 1.65 | 1.66 | 2.05 | 2.15 | 2.45 | 2.65 | 2.31 | 3.07 | 3.82 | 3.62 | 3.66 | 3.67 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 0.76 | 0.74 | 0.66 | 0.64 | 0.64 | 0.63 | 0.64 | 0.64 | 0.65 | 0.66 | 0.70 | 0.72 | 0.69 | 0.67 | 0.65 | 0.83 | 0.96 | 1.27 | ||||||
| Thermo Fisher Scientific Inc. | — | 4.87 | 4.87 | 4.85 | 4.47 | 4.57 | 4.82 | 5.06 | 4.62 | 4.83 | 4.93 | 5.06 | 4.83 | 4.64 | 4.62 | 4.60 | 4.29 | 4.03 | 3.87 | ||||||
| Vertex Pharmaceuticals Inc. | — | 1.00 | 0.95 | 0.98 | 0.99 | 1.06 | 1.14 | 1.27 | 1.37 | 1.53 | 1.65 | 1.71 | 1.71 | 1.90 | 2.06 | 2.35 | 2.69 | 2.70 | 2.83 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q3 2026 Calculation
Inventory turnover
= (Cost of salesQ3 2026
+ Cost of salesQ2 2026
+ Cost of salesQ1 2026
+ Cost of salesQ4 2025)
÷ Inventories
= (2,717 + 2,654 + 2,360 + 2,872)
÷ 3,134 = 3.38
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a fluctuating pattern in inventory management and cost efficiency from April 2022 through September 2026. While the cost of sales experienced significant volatility in the initial period, the latter half of the timeline shows a more stabilized cost base interrupted by a sharp increase in inventory levels during the first half of 2026, which adversely affected turnover efficiency.
- Inventory Level Dynamics
- Inventories peaked at 3,383 million US$ in March 2023 before entering a prolonged period of reduction, reaching a low of 2,330 million US$ by December 2024. This downward trend suggests a period of aggressive inventory lean-out or optimized supply chain management. However, this trend reversed sharply in mid-2026, with inventory levels climbing to 3,260 million US$ by June 2026, representing a significant buildup of stock within a short window.
- Cost of Sales Trends
- Cost of sales exhibited a peak of 3,430 million US$ in December 2022, followed by a contraction throughout 2023, where quarterly values generally fluctuated between 2,287 million US$ and 2,626 million US$. A moderate recovery in spending is observed toward the end of 2025, peaking at 2,872 million US$ in December 2025, before stabilizing around 2,700 million US$ in the final quarters of 2026.
- Inventory Turnover Efficiency
- The inventory turnover ratio demonstrates a cyclical pattern, oscillating between a high of 4.15 in December 2024 and a low of 3.20 in June 2026. The peak in December 2024 coincides with the lowest recorded inventory levels, indicating maximum operational efficiency in moving stock relative to costs. Conversely, the decline to 3.20 in June 2026 reflects a decoupling where inventory growth outpaced the growth in the cost of sales, resulting in slower inventory liquidation and reduced efficiency.
Overall, the data indicates a high level of sensitivity in the turnover ratio to changes in inventory stockpiling. The efficiency gains achieved throughout 2024 were largely erased by the inventory surge in 2026, suggesting a shift in procurement strategy or an anticipation of increased demand that has not yet been fully realized in the cost of sales figures.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Receivables Turnover
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Sales | 6,554) | 6,265) | 5,951) | 6,838) | 6,053) | 5,936) | 5,741) | 6,538) | 5,798) | 5,743) | 5,796) | 6,405) | 5,624) | 5,912) | 5,949) | 8,369) | 7,663) | 7,751) | 7,688) | ||||||
| Trade accounts receivable, less allowance for doubtful accounts | 4,126) | 3,965) | 3,819) | 3,913) | 3,755) | 3,564) | 3,506) | 3,537) | 3,507) | 3,298) | 3,379) | 3,922) | 4,201) | 4,199) | 4,313) | 4,918) | 4,409) | 4,527) | 4,407) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Receivables turnover1 | 6.21 | 6.33 | 6.49 | 6.28 | 6.46 | 6.74 | 6.79 | 6.75 | 6.77 | 7.15 | 7.02 | 6.09 | 6.15 | 6.64 | 6.89 | 6.40 | 7.09 | 6.81 | 6.87 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | 4.66 | 5.03 | 4.86 | 4.67 | 4.62 | 4.60 | 5.16 | 4.84 | 4.69 | 4.55 | 4.87 | 4.83 | 4.88 | 4.95 | 5.16 | 5.38 | 5.10 | 5.29 | ||||||
| Amgen Inc. | — | 3.55 | 3.88 | 3.67 | 4.06 | 3.85 | 4.03 | 4.72 | 4.26 | 4.26 | 4.16 | 3.70 | 4.17 | 4.34 | 4.34 | 4.46 | 4.60 | 4.62 | 4.81 | ||||||
| Eli Lilly & Co. | — | 3.97 | 3.92 | 3.67 | 3.69 | 3.76 | 4.07 | 4.09 | 3.97 | 3.53 | 4.56 | 3.75 | 3.93 | 3.93 | 3.68 | 4.14 | 4.35 | 4.57 | 4.64 | ||||||
| Gilead Sciences Inc. | — | 5.90 | 6.17 | 5.89 | 5.60 | 6.01 | 6.51 | 6.47 | 6.14 | 5.92 | 5.84 | 5.78 | 5.68 | 6.43 | 6.43 | 5.65 | 6.16 | 6.60 | 7.18 | ||||||
| Johnson & Johnson | 5.23 | 5.14 | 5.44 | 5.48 | 5.23 | 5.08 | 5.58 | 5.98 | 5.42 | 5.48 | 5.73 | 5.73 | 5.91 | 5.36 | 5.65 | 5.88 | 6.04 | 5.92 | 6.08 | ||||||
| Merck & Co. Inc. | — | 5.30 | 5.39 | 5.52 | 5.30 | 5.37 | 5.92 | 6.24 | 5.55 | 5.37 | 5.40 | 5.81 | 5.71 | 5.29 | 5.56 | 6.27 | 6.22 | 5.93 | 5.49 | ||||||
| Pfizer Inc. | — | 5.10 | 5.03 | 5.27 | 4.40 | 5.29 | 5.27 | 5.55 | 4.18 | 4.93 | 5.09 | 5.33 | 6.25 | 7.66 | 7.57 | 9.16 | 6.21 | 6.68 | 6.99 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 2.37 | 2.60 | 2.50 | 2.51 | 2.53 | 2.53 | 2.29 | 2.27 | 2.36 | 2.51 | 2.31 | 2.35 | 2.47 | 2.42 | 2.28 | 2.47 | 2.76 | 3.41 | ||||||
| Thermo Fisher Scientific Inc. | — | 4.90 | 4.91 | 5.01 | 4.91 | 5.03 | 5.07 | 5.23 | 5.13 | 5.33 | 5.36 | 5.21 | 5.19 | 5.43 | 5.53 | 5.53 | 5.76 | 5.53 | 5.21 | ||||||
| Vertex Pharmaceuticals Inc. | — | 5.90 | 6.12 | 5.85 | 6.02 | 6.03 | 6.15 | 6.85 | 6.07 | 6.24 | 5.68 | 6.31 | 6.27 | 6.11 | 5.95 | 6.19 | 6.28 | 6.26 | 6.15 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q3 2026 Calculation
Receivables turnover
= (SalesQ3 2026
+ SalesQ2 2026
+ SalesQ1 2026
+ SalesQ4 2025)
÷ Trade accounts receivable, less allowance for doubtful accounts
= (6,554 + 6,265 + 5,951 + 6,838)
÷ 4,126 = 6.21
2 Click competitor name to see calculations.
The analysis of operating activity reveals a fluctuating relationship between sales volume and the efficiency of receivables collection over the period from April 2022 through September 2026. A general contraction in sales occurred between early 2022 and early 2023, which was accompanied by a corresponding reduction in trade accounts receivable.
- Sales and Receivables Dynamics
- Sales reached a peak in December 2022 at 8,369 million USD before experiencing a notable decline throughout 2023. Trade accounts receivable followed a similar trajectory, peaking in December 2022 at 4,918 million USD and reaching a low of 3,298 million USD by June 2024. This suggests a proportional alignment between revenue generation and the credit extended to customers during the initial period of contraction.
- Receivables Turnover Efficiency
- The receivables turnover ratio exhibited volatility, ranging from a low of 6.09 in December 2023 to a high of 7.15 in June 2024. The peak in June 2024 indicates the highest level of efficiency in converting receivables into cash during the analyzed period. This peak followed a period of significant improvement in collection efficiency throughout the first half of 2024.
- Long-term Trend Analysis
- Following the efficiency peak in mid-2024, a gradual downward trend in the turnover ratio is observed, descending to 6.21 by September 2026. This decline coincides with a steady increase in trade accounts receivable, which rose from 3,298 million USD in June 2024 to 4,126 million USD in September 2026. Because the growth in receivables outpaced the growth in sales during this final phase, the resulting decrease in the turnover ratio suggests a deceleration in the collection cycle.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Payables Turnover
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Cost of sales | 2,717) | 2,654) | 2,360) | 2,872) | 2,530) | 2,413) | 2,230) | 2,648) | 2,397) | 2,315) | 2,309) | 2,626) | 2,349) | 2,594) | 2,287) | 3,430) | 3,079) | 3,030) | 2,983) | ||||||
| Trade accounts payable | 1,742) | 1,822) | 1,790) | 1,844) | 1,698) | 1,725) | 1,722) | 1,753) | 1,596) | 1,645) | 1,679) | 1,766) | 1,894) | 1,956) | 2,081) | 2,296) | 2,191) | 2,419) | 2,357) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Payables turnover1 | 6.09 | 5.72 | 5.68 | 5.45 | 5.78 | 5.62 | 5.57 | 5.52 | 6.04 | 5.84 | 5.88 | 5.58 | 5.63 | 5.82 | 5.68 | 5.45 | 5.61 | 5.00 | 5.04 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | — | 4.05 | 4.02 | 5.09 | 4.29 | 4.12 | 5.25 | 6.74 | 5.99 | 5.01 | 6.10 | 5.32 | 5.22 | 5.67 | 4.97 | 4.08 | 5.30 | 5.09 | 4.65 | ||||||
| Bristol-Myers Squibb Co. | — | 3.53 | 3.38 | 3.90 | 3.42 | 2.61 | 3.52 | 3.88 | 3.43 | 3.05 | 3.12 | 3.28 | 3.75 | 3.38 | 3.20 | 3.33 | 3.82 | 3.41 | 3.25 | ||||||
| Eli Lilly & Co. | — | 2.16 | 2.47 | 2.05 | 2.37 | 2.27 | 2.61 | 2.61 | 2.70 | 2.56 | 2.88 | 2.73 | 2.81 | 2.65 | 3.07 | 3.43 | 4.24 | 4.21 | 5.24 | ||||||
| Gilead Sciences Inc. | — | 9.22 | 9.52 | 8.72 | 7.66 | 10.65 | 8.47 | 7.50 | 7.49 | 12.57 | 10.69 | 11.81 | 9.90 | 9.06 | 8.99 | 6.25 | 11.22 | 11.89 | 11.43 | ||||||
| Johnson & Johnson | 3.46 | 3.41 | 2.96 | 2.52 | 3.06 | 3.07 | 2.97 | 2.66 | 3.03 | 3.03 | 3.23 | 2.76 | 3.29 | 2.75 | 3.05 | 2.66 | 3.08 | 3.15 | 3.26 | ||||||
| Merck & Co. Inc. | — | 4.70 | 4.44 | 3.72 | 3.53 | 3.82 | 3.98 | 3.72 | 4.26 | 4.39 | 4.48 | 4.11 | 4.59 | 4.58 | 4.34 | 4.08 | 5.16 | 4.86 | 4.25 | ||||||
| Pfizer Inc. | — | 3.73 | 3.72 | 3.07 | 3.32 | 3.44 | 3.30 | 3.17 | 3.67 | 4.60 | 4.19 | 3.72 | 5.07 | 3.92 | 4.78 | 5.04 | 5.49 | 6.17 | 6.66 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 2.03 | 2.24 | 2.24 | 2.30 | 2.83 | 2.84 | 2.50 | 3.87 | 3.32 | 2.67 | 2.99 | 3.43 | 3.14 | 2.69 | 2.65 | 3.74 | 4.00 | 5.39 | ||||||
| Thermo Fisher Scientific Inc. | — | 8.39 | 8.00 | 7.27 | 8.23 | 8.53 | 8.25 | 8.18 | 9.63 | 9.85 | 9.91 | 8.97 | 10.41 | 10.82 | 9.35 | 7.67 | 9.93 | 8.84 | 7.96 | ||||||
| Vertex Pharmaceuticals Inc. | — | 4.10 | 3.44 | 3.58 | 3.83 | 3.59 | 3.49 | 3.71 | 3.73 | 4.27 | 3.81 | 3.46 | 3.13 | 3.16 | 3.41 | 3.55 | 8.23 | 5.01 | 5.52 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q3 2026 Calculation
Payables turnover
= (Cost of salesQ3 2026
+ Cost of salesQ2 2026
+ Cost of salesQ1 2026
+ Cost of salesQ4 2025)
÷ Trade accounts payable
= (2,717 + 2,654 + 2,360 + 2,872)
÷ 1,742 = 6.09
2 Click competitor name to see calculations.
An analysis of the operating activity ratios from April 2022 through September 2026 reveals a general increase in the payables turnover ratio, reflecting a shift in the management of short-term obligations. While the cost of sales exhibits cyclical fluctuations, the total trade accounts payable decreased significantly during the first half of the period before stabilizing, resulting in a higher turnover rate.
- Cost of Sales Trends
- Cost of sales demonstrates a recurring seasonal pattern, with peak expenditures consistently occurring in the December quarters. The highest expenditure was recorded in December 2022 at 3,430 million US$, followed by subsequent year-end peaks in December 2024 (2,648 million US$) and December 2025 (2,872 million US$). Outside of these peaks, costs typically fluctuate between 2,230 million US$ and 2,717 million US$, indicating a stabilization of direct costs after the 2022 period.
- Trade Accounts Payable Evolution
- A sustained downward trend in trade accounts payable is observed from April 2022, where obligations stood at 2,357 million US$, falling to a low of 1,596 million US$ by September 2024. Following this decline, payables entered a period of relative stability, fluctuating within a narrow range between 1,698 million US$ and 1,844 million US$ through the remainder of the analyzed period. This reduction suggests either a strategic move to reduce liabilities or an acceleration in the settlement of supplier obligations.
- Payables Turnover Ratio Analysis
- The payables turnover ratio increased from a baseline of approximately 5.00 in early 2022 to a peak of 6.09 by September 2026. The ratio remained largely stable between 5.45 and 6.09 from March 2023 onward. The upward trajectory in this ratio, coupled with the decline in absolute payable balances, indicates that the company is cycling through its accounts payable more rapidly. This suggests a shorter payment cycle and a more aggressive approach to clearing short-term vendor liabilities relative to the volume of goods and services consumed.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Working Capital Turnover
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Current assets | 14,787) | 13,381) | 13,935) | 12,756) | 9,606) | 10,999) | 9,525) | 9,497) | 10,060) | 9,609) | 14,372) | 13,937) | 21,205) | 17,461) | 16,532) | 15,883) | 14,250) | 13,229) | 12,670) | ||||||
| Less: Current liabilities | 9,050) | 8,105) | 7,460) | 6,807) | 6,324) | 6,792) | 6,645) | 6,798) | 7,339) | 6,701) | 7,778) | 8,274) | 9,367) | 8,404) | 8,730) | 8,389) | 8,002) | 7,556) | 7,547) | ||||||
| Working capital | 5,737) | 5,276) | 6,475) | 5,949) | 3,282) | 4,207) | 2,880) | 2,699) | 2,721) | 2,908) | 6,594) | 5,663) | 11,838) | 9,057) | 7,802) | 7,494) | 6,248) | 5,673) | 5,123) | ||||||
| Sales | 6,554) | 6,265) | 5,951) | 6,838) | 6,053) | 5,936) | 5,741) | 6,538) | 5,798) | 5,743) | 5,796) | 6,405) | 5,624) | 5,912) | 5,949) | 8,369) | 7,663) | 7,751) | 7,688) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Working capital turnover1 | 4.46 | 4.76 | 3.83 | 4.13 | 7.39 | 5.71 | 8.27 | 8.85 | 8.73 | 8.10 | 3.60 | 4.22 | 2.18 | 3.08 | 3.81 | 4.20 | 5.00 | 5.43 | 5.91 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Amgen Inc. | — | 3.83 | 5.44 | 9.85 | 5.66 | 5.35 | 8.36 | 5.40 | 4.83 | 5.19 | 3.39 | 2.25 | 0.81 | 0.84 | 0.82 | 3.82 | 2.52 | 3.67 | 4.34 | ||||||
| Bristol-Myers Squibb Co. | — | 4.81 | 5.84 | 7.83 | 6.20 | 8.09 | 6.87 | 7.79 | 8.49 | 12.50 | 15.56 | 4.60 | 10.47 | 5.53 | 5.55 | 8.30 | 5.75 | 4.92 | 6.24 | ||||||
| Eli Lilly & Co. | — | 4.71 | 3.97 | 3.19 | 2.71 | 4.92 | 4.38 | 10.32 | 6.06 | 12.62 | 5.45 | — | 31.79 | 12.21 | 5.77 | 31.84 | 14.71 | 19.45 | 8.19 | ||||||
| Gilead Sciences Inc. | — | 10.20 | 3.19 | 4.43 | 5.12 | 8.14 | 6.27 | 3.99 | 9.22 | 17.98 | 26.58 | 5.61 | 6.74 | 84.15 | 9.14 | 8.42 | 8.56 | 6.87 | 6.68 | ||||||
| Johnson & Johnson | 111.11 | 20.07 | 66.14 | 62.88 | 24.63 | 284.99 | 6.10 | 15.94 | 58.86 | 22.29 | 10.35 | 11.81 | 9.37 | 14.06 | 23.02 | — | 4.88 | 5.02 | 5.57 | ||||||
| Merck & Co. Inc. | — | 7.44 | 8.15 | 4.28 | 3.39 | 5.77 | 6.19 | 6.19 | 5.86 | 5.14 | 9.68 | 9.29 | 6.69 | 8.86 | 5.63 | 5.16 | 5.58 | 6.39 | 6.09 | ||||||
| Pfizer Inc. | — | 7.31 | 7.47 | 10.58 | 6.08 | 10.68 | 6.64 | 8.64 | 5,036.00 | — | 29.17 | — | 1.62 | 2.03 | 6.89 | 11.00 | 3.83 | 5.05 | 6.10 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 1.20 | 1.14 | 1.05 | 1.05 | 1.08 | 1.01 | 0.97 | 0.88 | 0.87 | 0.86 | 0.82 | 0.87 | 0.92 | 0.90 | 0.96 | 1.09 | 1.14 | 1.46 | ||||||
| Thermo Fisher Scientific Inc. | — | 5.59 | 5.87 | 3.30 | 5.90 | 3.64 | 4.20 | 4.87 | 4.61 | 3.96 | 4.38 | 4.05 | 4.86 | 7.40 | 10.13 | 5.46 | 5.40 | 6.03 | 6.13 | ||||||
| Vertex Pharmaceuticals Inc. | — | 1.46 | 1.56 | 1.64 | 1.92 | 1.82 | 1.78 | 1.83 | 1.82 | 1.92 | 1.07 | 0.93 | 0.87 | 0.90 | 0.93 | 0.85 | 0.90 | 0.93 | 0.97 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q3 2026 Calculation
Working capital turnover
= (SalesQ3 2026
+ SalesQ2 2026
+ SalesQ1 2026
+ SalesQ4 2025)
÷ Working capital
= (6,554 + 6,265 + 5,951 + 6,838)
÷ 5,737 = 4.46
2 Click competitor name to see calculations.
The analysis of working capital turnover reveals a highly volatile trajectory characterized by three distinct operational phases: a period of efficiency decline, a phase of aggressive capital optimization, and a subsequent period of normalization and fluctuation.
- Initial Efficiency Decline (April 2022 – September 2023)
- A consistent downward trend in the turnover ratio is observed, falling from a high of 5.91 to a low of 2.18. This decline was driven by a substantial expansion in working capital, which increased from 5,123 million to 11,838 million. During this same period, sales experienced overall stagnation or decline, peaking at 8,369 million in December 2022 before falling to 5,624 million by September 2023, indicating a growing imbalance between operating liquidity and revenue generation.
- Rapid Capital Optimization (December 2023 – September 2024)
- A sharp reversal in the trend occurred starting in late 2023, with the turnover ratio peaking at 8.85 in September 2024. This surge is directly attributable to a significant reduction in working capital, which plummeted from its peak of 11,838 million to 2,721 million. The rapid increase in the ratio suggests an aggressive optimization of short-term assets and liabilities or a significant liquidation of working capital components, which enhanced the efficiency of sales generation relative to the capital employed.
- Stabilization and Recurrence (December 2024 – September 2026)
- The final period is characterized by fluctuating turnover ratios, generally ranging between 3.83 and 7.39. Working capital levels began to climb again, reaching 6,475 million in March 2026, which coincided with a moderation of the turnover ratio to 3.83. A subsequent recovery in the ratio to 4.46 by September 2026 corresponds with a relative stabilization of sales at 6,554 million and a slight reduction in working capital to 5,737 million, suggesting a return to a more sustainable, albeit variable, operating cycle.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Inventory Processing Period
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Inventory turnover | 3.38 | 3.20 | 3.90 | 4.04 | 3.67 | 3.60 | 3.79 | 4.15 | 3.60 | 3.59 | 3.73 | 3.80 | 3.53 | 3.58 | 3.50 | 4.03 | 3.80 | 3.71 | 3.87 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average inventory processing period1 | 108 | 114 | 94 | 90 | 99 | 101 | 96 | 88 | 101 | 102 | 98 | 96 | 104 | 102 | 104 | 91 | 96 | 98 | 94 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | 102 | 100 | 99 | 100 | 107 | 98 | 90 | 89 | 75 | 75 | 73 | 77 | 85 | 81 | 75 | 66 | 73 | 74 | ||||||
| Amgen Inc. | — | 195 | 191 | 189 | 190 | 194 | 195 | 199 | 209 | 257 | 321 | 411 | 259 | 265 | 279 | 281 | 272 | 260 | 247 | ||||||
| Bristol-Myers Squibb Co. | — | 68 | 70 | 70 | 69 | 70 | 69 | 67 | 102 | 98 | 99 | 91 | 84 | 83 | 93 | 84 | 76 | 79 | 80 | ||||||
| Eli Lilly & Co. | — | 463 | 428 | 454 | 441 | 435 | 379 | 329 | 349 | 316 | 312 | 298 | 261 | 267 | 268 | 237 | 196 | 204 | 189 | ||||||
| Gilead Sciences Inc. | — | 115 | 114 | 104 | 105 | 108 | 103 | 100 | 101 | 110 | 102 | 100 | 105 | 106 | 102 | 97 | 78 | 81 | 81 | ||||||
| Johnson & Johnson | 174 | 176 | 172 | 171 | 176 | 168 | 163 | 165 | 169 | 166 | 158 | 154 | 149 | 164 | 155 | 147 | 136 | 136 | 132 | ||||||
| Merck & Co. Inc. | — | 126 | 138 | 148 | 160 | 162 | 150 | 147 | 149 | 153 | 151 | 144 | 139 | 137 | 134 | 124 | 118 | 119 | 133 | ||||||
| Pfizer Inc. | — | 212 | 232 | 242 | 251 | 239 | 229 | 222 | 219 | 178 | 170 | 149 | 138 | 158 | 119 | 95 | 101 | 100 | 99 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 479 | 491 | 556 | 571 | 570 | 582 | 572 | 573 | 562 | 553 | 519 | 508 | 532 | 549 | 562 | 440 | 379 | 287 | ||||||
| Thermo Fisher Scientific Inc. | — | 75 | 75 | 75 | 82 | 80 | 76 | 72 | 79 | 76 | 74 | 72 | 76 | 79 | 79 | 79 | 85 | 91 | 94 | ||||||
| Vertex Pharmaceuticals Inc. | — | 365 | 384 | 373 | 369 | 345 | 320 | 287 | 267 | 238 | 222 | 214 | 213 | 192 | 177 | 156 | 136 | 135 | 129 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q3 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.38 = 108
2 Click competitor name to see calculations.
The average inventory processing period exhibits a fluctuating trend between April 2022 and September 2026, with the duration of inventory holdings ranging from a minimum of 88 days to a maximum of 114 days. There is a consistent inverse correlation between the inventory turnover ratio and the processing period, where peaks in turnover correspond directly with reductions in the number of days required to process inventory.
- Efficiency Trends and Peaks
- A period of heightened operational efficiency was observed toward the end of 2024. The average inventory processing period reached its lowest point of 88 days on December 31, 2024, coinciding with the highest inventory turnover ratio of 4.15. This represents the optimal point of inventory movement within the analyzed timeframe.
- Period of Inventory Accumulation
- An upward trend in the processing period was evident during much of 2023, with the duration peaking at 104 days in March and September 2023. This indicates a slower movement of goods compared to the 2022 baseline, where the processing period generally remained between 91 and 98 days.
- Recent Performance Deterioration
- The data indicates a significant increase in the inventory processing period during the first half of 2026. The duration rose sharply to 114 days by June 26, 2026, the highest level in the provided series. This spike corresponds with a decline in the inventory turnover ratio to its lowest point of 3.20, suggesting a substantial slowdown in inventory liquidation or a strategic increase in stock levels.
- Stabilization Patterns
- Throughout 2025, the processing period remained relatively stable, oscillating between 90 and 101 days. This period of stability followed the efficiency gains of late 2024 but preceded the volatility observed in 2026.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Receivable Collection Period
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Receivables turnover | 6.21 | 6.33 | 6.49 | 6.28 | 6.46 | 6.74 | 6.79 | 6.75 | 6.77 | 7.15 | 7.02 | 6.09 | 6.15 | 6.64 | 6.89 | 6.40 | 7.09 | 6.81 | 6.87 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average receivable collection period1 | 59 | 58 | 56 | 58 | 56 | 54 | 54 | 54 | 54 | 51 | 52 | 60 | 59 | 55 | 53 | 57 | 51 | 54 | 53 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | 78 | 73 | 75 | 78 | 79 | 79 | 71 | 75 | 78 | 80 | 75 | 76 | 75 | 74 | 71 | 68 | 72 | 69 | ||||||
| Amgen Inc. | — | 103 | 94 | 99 | 90 | 95 | 91 | 77 | 86 | 86 | 88 | 99 | 88 | 84 | 84 | 82 | 79 | 79 | 76 | ||||||
| Eli Lilly & Co. | — | 92 | 93 | 99 | 99 | 97 | 90 | 89 | 92 | 103 | 80 | 97 | 93 | 93 | 99 | 88 | 84 | 80 | 79 | ||||||
| Gilead Sciences Inc. | — | 62 | 59 | 62 | 65 | 61 | 56 | 56 | 59 | 62 | 62 | 63 | 64 | 57 | 57 | 65 | 59 | 55 | 51 | ||||||
| Johnson & Johnson | 70 | 71 | 67 | 67 | 70 | 72 | 65 | 61 | 67 | 67 | 64 | 64 | 62 | 68 | 65 | 62 | 60 | 62 | 60 | ||||||
| Merck & Co. Inc. | — | 69 | 68 | 66 | 69 | 68 | 62 | 58 | 66 | 68 | 68 | 63 | 64 | 69 | 66 | 58 | 59 | 62 | 66 | ||||||
| Pfizer Inc. | — | 72 | 73 | 69 | 83 | 69 | 69 | 66 | 87 | 74 | 72 | 69 | 58 | 48 | 48 | 40 | 59 | 55 | 52 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 154 | 140 | 146 | 146 | 144 | 144 | 160 | 161 | 155 | 146 | 158 | 156 | 148 | 151 | 160 | 148 | 132 | 107 | ||||||
| Thermo Fisher Scientific Inc. | — | 74 | 74 | 73 | 74 | 73 | 72 | 70 | 71 | 68 | 68 | 70 | 70 | 67 | 66 | 66 | 63 | 66 | 70 | ||||||
| Vertex Pharmaceuticals Inc. | — | 62 | 60 | 62 | 61 | 61 | 59 | 53 | 60 | 58 | 64 | 58 | 58 | 60 | 61 | 59 | 58 | 58 | 59 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q3 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.21 = 59
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a pattern of moderate volatility in the efficiency of receivable collections, with a noticeable trend toward longer collection cycles in the latter half of the observed period.
- Average Receivable Collection Period Trends
- The average receivable collection period fluctuated between a minimum of 51 days in June 2024 and a maximum of 60 days in December 2023. An optimization of collection efficiency occurred during the first half of 2024, reaching the lowest point in the sequence. However, from June 2024 through September 2026, a steady increase is observed, with the collection period extending from 51 days to 59 days.
- Receivables Turnover Dynamics
- The receivables turnover ratio exhibits an inverse relationship with the collection period. A peak turnover ratio of 7.15 was recorded in June 2024, aligning with the period of maximum collection efficiency. Subsequently, the turnover ratio trended downward, declining to 6.21 by September 2026. This decline reflects a slowing rate of receivable conversion over the final two years of the analyzed timeframe.
- Operational Efficiency Assessment
- While the collection period has remained within a relatively stable band of 51 to 60 days, the trajectory since mid-2024 indicates a marginal deterioration in liquidity management. The increase in the collection period toward the end of the series suggests a gradual slowing in the cash conversion cycle regarding trade receivables.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Operating Cycle
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | 108 | 114 | 94 | 90 | 99 | 101 | 96 | 88 | 101 | 102 | 98 | 96 | 104 | 102 | 104 | 91 | 96 | 98 | 94 | ||||||
| Average receivable collection period | 59 | 58 | 56 | 58 | 56 | 54 | 54 | 54 | 54 | 51 | 52 | 60 | 59 | 55 | 53 | 57 | 51 | 54 | 53 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Operating cycle1 | 167 | 172 | 150 | 148 | 155 | 155 | 150 | 142 | 155 | 153 | 150 | 156 | 163 | 157 | 157 | 148 | 147 | 152 | 147 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | — | 180 | 173 | 174 | 178 | 186 | 177 | 161 | 164 | 153 | 155 | 148 | 153 | 160 | 155 | 146 | 134 | 145 | 143 | ||||||
| Amgen Inc. | — | 298 | 285 | 288 | 280 | 289 | 286 | 276 | 295 | 343 | 409 | 510 | 347 | 349 | 363 | 363 | 351 | 339 | 323 | ||||||
| Eli Lilly & Co. | — | 555 | 521 | 553 | 540 | 532 | 469 | 418 | 441 | 419 | 392 | 395 | 354 | 360 | 367 | 325 | 280 | 284 | 268 | ||||||
| Gilead Sciences Inc. | — | 177 | 173 | 166 | 170 | 169 | 159 | 156 | 160 | 172 | 164 | 163 | 169 | 163 | 159 | 162 | 137 | 136 | 132 | ||||||
| Johnson & Johnson | 244 | 247 | 239 | 238 | 246 | 240 | 228 | 226 | 236 | 233 | 222 | 218 | 211 | 232 | 220 | 209 | 196 | 198 | 192 | ||||||
| Merck & Co. Inc. | — | 195 | 206 | 214 | 229 | 230 | 212 | 205 | 215 | 221 | 219 | 207 | 203 | 206 | 200 | 182 | 177 | 181 | 199 | ||||||
| Pfizer Inc. | — | 284 | 305 | 311 | 334 | 308 | 298 | 288 | 306 | 252 | 242 | 218 | 196 | 206 | 167 | 135 | 160 | 155 | 151 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 633 | 631 | 702 | 717 | 714 | 726 | 732 | 734 | 717 | 699 | 677 | 664 | 680 | 700 | 722 | 588 | 511 | 394 | ||||||
| Thermo Fisher Scientific Inc. | — | 149 | 149 | 148 | 156 | 153 | 148 | 142 | 150 | 144 | 142 | 142 | 146 | 146 | 145 | 145 | 148 | 157 | 164 | ||||||
| Vertex Pharmaceuticals Inc. | — | 427 | 444 | 435 | 430 | 406 | 379 | 340 | 327 | 296 | 286 | 272 | 271 | 252 | 238 | 215 | 194 | 193 | 188 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q3 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 108 + 59 = 167
2 Click competitor name to see calculations.
The operating cycle exhibits a period of relative stability from early 2022 through 2025, followed by a notable expansion in duration during the first half of 2026. The overall cycle fluctuates between a minimum of 142 days and a maximum of 172 days, with the primary driver of volatility being the inventory processing phase rather than the collection of receivables.
- Average Inventory Processing Period
- Inventory duration shows moderate volatility, generally oscillating between 88 and 104 days for the majority of the observed period. A significant low was recorded on December 31, 2024, at 88 days. However, a distinct upward trend emerged in 2026, peaking at 114 days on June 26, 2026, indicating a slowdown in inventory turnover toward the end of the sequence.
- Average Receivable Collection Period
- The collection period remains highly consistent, maintaining a tight range between 51 and 60 days. The narrow variance suggests a disciplined and predictable credit management process, with no significant deviations or systemic delays in payment collection throughout the multi-year period.
- Operating Cycle Total
- The total operating cycle closely mirrors the movements of the inventory processing period due to the stability of receivables. After remaining largely between 142 and 163 days from 2022 to 2025, the cycle experienced a sharp increase to 172 days by June 2026. This expansion indicates a longer window between the initial outlay for inventory and the eventual conversion of sales into cash.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Average Payables Payment Period
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Payables turnover | 6.09 | 5.72 | 5.68 | 5.45 | 5.78 | 5.62 | 5.57 | 5.52 | 6.04 | 5.84 | 5.88 | 5.58 | 5.63 | 5.82 | 5.68 | 5.45 | 5.61 | 5.00 | 5.04 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average payables payment period1 | 60 | 64 | 64 | 67 | 63 | 65 | 66 | 66 | 60 | 63 | 62 | 65 | 65 | 63 | 64 | 67 | 65 | 73 | 72 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | — | 90 | 91 | 72 | 85 | 89 | 70 | 54 | 61 | 73 | 60 | 69 | 70 | 64 | 73 | 90 | 69 | 72 | 78 | ||||||
| Bristol-Myers Squibb Co. | — | 103 | 108 | 94 | 107 | 140 | 104 | 94 | 106 | 120 | 117 | 111 | 97 | 108 | 114 | 109 | 96 | 107 | 112 | ||||||
| Eli Lilly & Co. | — | 169 | 148 | 178 | 154 | 161 | 140 | 140 | 135 | 142 | 127 | 134 | 130 | 138 | 119 | 106 | 86 | 87 | 70 | ||||||
| Gilead Sciences Inc. | — | 40 | 38 | 42 | 48 | 34 | 43 | 49 | 49 | 29 | 34 | 31 | 37 | 40 | 41 | 58 | 33 | 31 | 32 | ||||||
| Johnson & Johnson | 106 | 107 | 123 | 145 | 119 | 119 | 123 | 137 | 120 | 121 | 113 | 132 | 111 | 133 | 120 | 137 | 118 | 116 | 112 | ||||||
| Merck & Co. Inc. | — | 78 | 82 | 98 | 103 | 95 | 92 | 98 | 86 | 83 | 81 | 89 | 80 | 80 | 84 | 89 | 71 | 75 | 86 | ||||||
| Pfizer Inc. | — | 98 | 98 | 119 | 110 | 106 | 110 | 115 | 99 | 79 | 87 | 98 | 72 | 93 | 76 | 72 | 66 | 59 | 55 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 180 | 163 | 163 | 158 | 129 | 129 | 146 | 94 | 110 | 137 | 122 | 106 | 116 | 136 | 138 | 98 | 91 | 68 | ||||||
| Thermo Fisher Scientific Inc. | — | 43 | 46 | 50 | 44 | 43 | 44 | 45 | 38 | 37 | 37 | 41 | 35 | 34 | 39 | 48 | 37 | 41 | 46 | ||||||
| Vertex Pharmaceuticals Inc. | — | 89 | 106 | 102 | 95 | 102 | 105 | 98 | 98 | 85 | 96 | 106 | 117 | 115 | 107 | 103 | 44 | 73 | 66 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q3 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 6.09 = 60
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a general trend of accelerating payments to suppliers over the observed period. The average payables payment period shifted from a peak of 73 days in mid-2022 to a low of 60 days by September 2026, indicating a tightening of the credit cycle and a more rapid settlement of accounts payable.
- Payables Turnover Dynamics
- An overall increase in the payables turnover ratio is observed, rising from 5.04 in April 2022 to 6.09 by September 2026. This upward trajectory signifies that the company is processing its obligations to suppliers more frequently, which corresponds with the reduction in the average payment window.
- Average Payables Payment Period Trends
- The payment period exhibited a notable decrease from the initial 72-73 day range in early 2022 to a stabilized range between 60 and 67 days throughout 2023, 2024, and 2025. Specific troughs of 60 days occurred in September 2024 and September 2026, representing the most accelerated points of liability liquidation within the reporting timeframe.
- Operational Efficiency and Working Capital
- A consistent inverse correlation is maintained between the turnover ratio and the payment period. The relative stability of these metrics, characterized by the absence of extreme volatility, suggests a disciplined approach to working capital management and a consistent strategy regarding supplier credit terms.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Cash Conversion Cycle
| Sep 25, 2026 | Jun 26, 2026 | Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Average inventory processing period | 108 | 114 | 94 | 90 | 99 | 101 | 96 | 88 | 101 | 102 | 98 | 96 | 104 | 102 | 104 | 91 | 96 | 98 | 94 | ||||||
| Average receivable collection period | 59 | 58 | 56 | 58 | 56 | 54 | 54 | 54 | 54 | 51 | 52 | 60 | 59 | 55 | 53 | 57 | 51 | 54 | 53 | ||||||
| Average payables payment period | 60 | 64 | 64 | 67 | 63 | 65 | 66 | 66 | 60 | 63 | 62 | 65 | 65 | 63 | 64 | 67 | 65 | 73 | 72 | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Cash conversion cycle1 | 107 | 108 | 86 | 81 | 92 | 90 | 84 | 76 | 95 | 90 | 88 | 91 | 98 | 94 | 93 | 81 | 82 | 79 | 75 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||||||
| Amgen Inc. | — | 208 | 194 | 216 | 195 | 200 | 216 | 222 | 234 | 270 | 349 | 441 | 277 | 285 | 290 | 273 | 282 | 267 | 245 | ||||||
| Eli Lilly & Co. | — | 386 | 373 | 375 | 386 | 371 | 329 | 278 | 306 | 277 | 265 | 261 | 224 | 222 | 248 | 219 | 194 | 197 | 198 | ||||||
| Gilead Sciences Inc. | — | 137 | 135 | 124 | 122 | 135 | 116 | 107 | 111 | 143 | 130 | 132 | 132 | 123 | 118 | 104 | 104 | 105 | 100 | ||||||
| Johnson & Johnson | 138 | 140 | 116 | 93 | 127 | 121 | 105 | 89 | 116 | 112 | 109 | 86 | 100 | 99 | 100 | 72 | 78 | 82 | 80 | ||||||
| Merck & Co. Inc. | — | 117 | 124 | 116 | 126 | 135 | 120 | 107 | 129 | 138 | 138 | 118 | 123 | 126 | 116 | 93 | 106 | 106 | 113 | ||||||
| Pfizer Inc. | — | 186 | 207 | 192 | 224 | 202 | 188 | 173 | 207 | 173 | 155 | 120 | 124 | 113 | 91 | 63 | 94 | 96 | 96 | ||||||
| Regeneron Pharmaceuticals Inc. | — | 453 | 468 | 539 | 559 | 585 | 597 | 586 | 640 | 607 | 562 | 555 | 558 | 564 | 564 | 584 | 490 | 420 | 326 | ||||||
| Thermo Fisher Scientific Inc. | — | 106 | 103 | 98 | 112 | 110 | 104 | 97 | 112 | 107 | 105 | 101 | 111 | 112 | 106 | 97 | 111 | 116 | 118 | ||||||
| Vertex Pharmaceuticals Inc. | — | 338 | 338 | 333 | 335 | 304 | 274 | 242 | 229 | 211 | 190 | 166 | 154 | 137 | 131 | 112 | 150 | 120 | 122 | ||||||
Based on: 10-Q (reporting date: 2026-09-25), 10-Q (reporting date: 2026-06-26), 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q3 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 108 + 59 – 60 = 107
2 Click competitor name to see calculations.
The cash conversion cycle exhibits a general expansionary trend over the observed period, moving from 75 days in April 2022 to 107 days by September 2026. This overall increase indicates a longer duration required to convert working capital into cash, driven primarily by fluctuations in inventory management and a slight compression in payables payment terms.
- Average Inventory Processing Period
- Inventory turnover displays the highest degree of volatility among the three components. The processing period fluctuated between a low of 88 days in December 2024 and a peak of 114 days in June 2026. The upward movement in inventory days serves as the primary catalyst for the lengthening of the overall cash conversion cycle.
- Average Receivable Collection Period
- Receivables collection remains relatively stable, with values ranging from a minimum of 51 days to a maximum of 60 days. This stability suggests a disciplined credit policy and predictable payment behavior from customers throughout the entire analysis period.
- Average Payables Payment Period
- A gradual contraction is observed in the payables payment period, which decreased from a high of 73 days in July 2022 to 60 days by September 2026. This reduction in the time taken to settle obligations to suppliers effectively increases the cash conversion cycle by reducing the duration of supplier-provided financing.
- Cash Conversion Cycle Synthesis
- The overall cycle shows distinct phases of expansion and contraction. While the cycle remained within a range of 75 to 98 days from early 2022 through early 2024, a more pronounced increase is evident from 2025 onward, culminating in a peak of 108 days in June 2026. The combination of increasing inventory hold times and decreasing payables terms has resulted in a less efficient cash flow cycle toward the end of the reported period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?